Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10001510HBVENSG00000100031.19protein_codingGGT1NoNo2678P19440
TVIS10023800HBVENSG00000100031.19protein_codingGGT1NoNo2678P19440
TVIS10029186HBVENSG00000100031.19protein_codingGGT1NoNo2678P19440
TVIS10050156HBVENSG00000100031.19protein_codingGGT1NoNo2678P19440
TVIS30055235HIVENSG00000100031.19protein_codingGGT1NoNo2678P19440
TVIS20056264HPVENSG00000100031.19protein_codingGGT1NoNo2678P19440
TVIS20056288HPVENSG00000100031.19protein_codingGGT1NoNo2678P19440
TVIS44012587HTLV-1ENSG00000100031.19protein_codingGGT1NoNo2678P19440
TCGA Plot Options
Drug Information
GeneGGT1
DrugBank IDDB00143
Drug NameGlutathione
Target IDBE0000889
UniProt IDP19440
Regulation Type
PubMed IDs17316176; 17545509; 17569287; 17644279; 17291629
CitationsOhkama-Ohtsu N, Zhao P, Xiang C, Oliver DJ: Glutathione conjugates in the vacuole are degraded by gamma-glutamyl transpeptidase GGT3 in Arabidopsis. Plant J. 2007 Mar;49(5):878-88.@@Martin MN, Saladores PH, Lambert E, Hudson AO, Leustek T: Localization of members of the gamma-glutamyl transpeptidase family identifies sites of glutathione and glutathione S-conjugate hydrolysis. Plant Physiol. 2007 Aug;144(4):1715-32. Epub 2007 Jun 1.@@Anilakumar KR, Nagaraj NS, Santhanam K: Reduction of hexachlorocyclohexane-induced oxidative stress and cytotoxicity in rat liver by Emblica officinalis gaertn. Indian J Exp Biol. 2007 May;45(5):450-4.@@Adamis PD, Panek AD, Eleutherio EC: Vacuolar compartmentation of the cadmium-glutathione complex protects Saccharomyces cerevisiae from mutagenesis. Toxicol Lett. 2007 Aug 30;173(1):1-7. Epub 2007 Jun 14.@@Zhu Y, Carvey PM, Ling Z: Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide. Neurochem Int. 2007 Mar;50(4):671-80. Epub 2007 Jan 13.
GroupsApproved; Investigational; Nutraceutical
Direct ClassificationPeptides
SMILESN[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O
PathwaysArachidonic Acid Metabolism; Flurbiprofen Action Pathway; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Oxaprozin Action Pathway; Rofecoxib Action Pathway; Pyruvate Kinase Deficiency; Acetaminophen Metabolism Pathway; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; 5-Oxoprolinuria; gamma-Glutamyltransferase Deficiency; Naproxen Action Pathway; Sulindac Action Pathway; Glutathione Synthetase Deficiency; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); Meloxicam Action Pathway; Cyclophosphamide Action Pathway; Succinic Semialdehyde Dehydrogenase Deficiency; Valdecoxib Action Pathway; Ketorolac Action Pathway; 5-Oxoprolinase Deficiency; Acetylsalicylic Acid Action Pathway; Antipyrine Action Pathway; Glutathione Metabolism; Diclofenac Action Pathway; Homocarnosinosis; Cyclophosphamide Metabolism Pathway; Nepafenac Action Pathway
PharmGKBPA449780
ChEMBLCHEMBL1543